Kyverna Therapeutics, Inc.
KYTXKyverna Therapeutics, Inc. in brief
Kyverna Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Emeryville, California, USA. Its market value was $341 M on 26 October 2026, which makes it the 14,253rd largest listed company in the world and the 2,792nd largest in the USA on this site. It employs about 130 people and Warner Weston Biddle is its chief executive. Its shares trade under the symbol KYTX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Kyverna Therapeutics, Inc.
We are a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Our mission is to liberate patients from autoimmune diseases through the curative potential of cell therapy. Our development strategy is supported by our breadth of experience in treating more than 100 autoimmune patients with our lead product candidate, mivocabtagene autoleucel, or miv-cel, also known as KYV-101, an anti-CD19 autologous CAR T with a differentiated CAR construct. This has been documented through the scientific publication of multiple autoimmune case studies, our proprietary dataset of patients treated through named patient forms of compassionate use, our experience in ongoing investigator-initiated trials, or IITs, at leading academic institutions, as well as early clinical data from our ongoing company-sponsored trials illustrating the potential of these therapies to deeply deplete B cells with the aim of achieving durable treatment-free remission. This validation provides us with a clear path to continue advancing miv-cel through late-stage clinical development and commercialization across multiple autoimmune indications.
From the company's annual report filed with the US SEC: read the report
Kyverna Therapeutics, Inc. timeline
- 2023
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2024
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 8 February 2024; shares registered for exchange trading on 5 February 2024.
Events of Kyverna Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,535 (Aug 2026) · #2,674 (Oct 2026) · #2,796 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.5×
- Free cash flow yield
- -45.1%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -69.4%
- Liabilities / assets
- 20.9%
- Net debt
- $-99M
- Profit per employee
- $-1.2 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-170M | $-161M | — |
| Dec 2024 | — | — | $-143M | $-127M | — |
| Dec 2023 | — | — | $-62M | $-60M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-154M | $0M | $-154M | $-3.64 | — |
| Dec 2024 | $-114M | $2M | $-116M | $-3.33 | — |
| Dec 2023 | $-52M | $1M | $-53M | $-89.61 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-42M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Sep 24, 20268-KCurrent reportRegulation FD disclosure
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Jul 27, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Jul 9, 20268-KCurrent reportMaterial agreement
- Jun 2, 20268-KCurrent reportShareholder vote
- May 18, 20268-KCurrent reportDirectors or officers changed · Other events
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations
- May 4, 20268-KCurrent reportOther events
Official filings of Kyverna Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-170 M
- Net income
- $-161 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $294 M
- Total liabilities
- $62 M
- Total equity
- $232 M
As of December-2025
Top 100 institutional investors in Kyverna Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | GordonMD Global Investments LP | 4,521,318 | +276,500 (+6.51%) | 7.15% | $31 M | Nov 16, 2026 |
| 2 | Gilead Sciences, Inc. | 4,126,119 | 0 (0.00%) | 6.53% | $28 M | Nov 6, 2026 |
| 3 | AIGH Capital Management LLC | 3,650,000 | +854,203 (+30.55%) | 5.77% | $25 M | Nov 2, 2026 |
| 4 | BlackRock, Inc. | 3,238,110 | +103,303 (+3.30%) | 5.12% | $22 M | Nov 13, 2026 |
| 5 | Vanguard Capital Management LLC | 2,011,138 | +113,687 (+5.99%) | 3.18% | $14 M | Nov 13, 2026 |
| 6 | Bain Capital Life Sciences Investors, LLC | 1,312,000 | -1,573,000 (-54.52%) | 2.08% | $9 M | Nov 16, 2026 |
| 7 | Price T Rowe Associates Inc /MD/ | 1,207,564 | +21,541 (+1.82%) | 1.91% | $8 M | Nov 16, 2026 |
| 8 | State Street Corp | 1,203,252 | +221,019 (+22.50%) | 1.90% | $8 M | Nov 12, 2026 |
| 9 | Geode Capital Management, LLC | 1,053,681 | +4,251 (+0.41%) | 1.67% | $7 M | Nov 6, 2026 |
| 10 | Insight Holdings Group, LLC | 989,054 | 0 (0.00%) | 1.56% | $7 M | Nov 16, 2026 |
| 11 | Millennium Management LLC | 826,137 | +186,357 (+29.13%) | 1.31% | $6 M | Nov 16, 2026 |
| 12 | Propel Bio Management, LLC | 700,595 | -182,603 (-20.68%) | 1.11% | $5 M | Nov 13, 2026 |
| 13 | MBB Public Markets I LLC | 614,477 | 0 (0.00%) | 0.97% | $4 M | Nov 16, 2026 |
| 14 | UBS Group AG | 599,284 | +233,710 (+63.93%) | 0.95% | $4 M | Nov 10, 2026 |
| 15 | Morgan Stanley | 552,246 | -430,061 (-43.78%) | 0.87% | $4 M | Nov 13, 2026 |
| 16 | Goldman Sachs Group Inc | 551,899 | +216,669 (+64.63%) | 0.87% | $4 M | Nov 16, 2026 |
| 17 | FMR LLC | 538,379 | +442,328 (+460.51%) | 0.85% | $4 M | Nov 10, 2026 |
| 18 | Adage Capital Partners GP, L.L.C. | 500,000 | 0 (0.00%) | 0.79% | $3 M | Nov 16, 2026 |
| 19 | Wells Fargo & Company/mn | 461,796 | +88,787 (+23.80%) | 0.73% | $3 M | Nov 16, 2026 |
| 20 | Woodline Partners LP | 423,325 | -422,000 (-49.92%) | 0.67% | $3 M | Nov 16, 2026 |
| 21 | Vanguard Portfolio Management LLC | 360,489 | +78,300 (+27.75%) | 0.57% | $2 M | Nov 13, 2026 |
| 22 | Charles Schwab Investment Management Inc | 333,505 | +13,839 (+4.33%) | 0.53% | $2 M | Nov 16, 2026 |
| 23 | Renaissance Technologies LLC | 327,821 | -6,078 (-1.82%) | 0.52% | $2 M | Nov 12, 2026 |
| 24 | Northern Trust Corp | 325,011 | +9,657 (+3.06%) | 0.51% | $2 M | Nov 16, 2026 |
| 25 | Dimensional Fund Advisors LP | 278,566 | +200,147 (+255.23%) | 0.44% | $2 M | Nov 4, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | BNP Paribas Financial Markets | 276,016 | -34,616 (-11.14%) | 0.44% | $2 M | Nov 12, 2026 |
| 27 | Vanguard Fiduciary Trust Co | 259,506 | -161 (-0.06%) | 0.41% | $2 M | Nov 13, 2026 |
| 28 | Nuveen, LLC | 239,940 | +6,197 (+2.65%) | 0.38% | $2 M | Nov 10, 2026 |
| 29 | Burkehill Global Management, LP | 200,000 | 0 (0.00%) | 0.32% | $1 M | Nov 16, 2026 |
| 30 | Point72 Asset Management, L.P. | 186,902 | New | 0.30% | $1 M | Nov 16, 2026 |
| 31 | Simplify Asset Management Inc. | 182,603 | 0 (0.00%) | 0.29% | $1 M | Oct 27, 2026 |
| 32 | Susquehanna International Group, LLP | 157,535 | +1,735 (+1.11%) | 0.25% | $1 M | Nov 16, 2026 |
| 33 | D. E. Shaw & Co., Inc. | 146,890 | -322,456 (-68.70%) | 0.23% | $1 M | Nov 16, 2026 |
| 34 | Wellington Management Group LLP | 146,346 | +28,904 (+24.61%) | 0.23% | $1 M | Nov 16, 2026 |
| 35 | TD Asset Management Inc | 145,682 | 0 (0.00%) | 0.23% | $1 M | Nov 13, 2026 |
| 36 | Stifel Financial Corp | 139,922 | -43 (-0.03%) | 0.22% | $1 M | Nov 12, 2026 |
| 37 | Citadel Advisors LLC | 137,034 | -10,593 (-7.18%) | 0.22% | $1 M | Nov 16, 2026 |
| 38 | Barclays PLC | 136,134 | +18,290 (+15.52%) | 0.22% | $1 M | Nov 6, 2026 |
| 39 | Raymond James Financial Inc | 128,993 | New | 0.20% | $1 M | Nov 12, 2026 |
| 40 | Bank of New York Mellon Corp | 104,452 | +4,171 (+4.16%) | 0.17% | $1 M | Nov 5, 2026 |
| 41 | Manufacturers Life Insurance Company, The | 100,700 | +18,493 (+22.50%) | 0.16% | $1 M | Nov 13, 2026 |
| 42 | Nano Cap New Millennium Growth Fund L P | 90,000 | +20,000 (+28.57%) | 0.14% | $1 M | Nov 13, 2026 |
| 43 | Susquehanna Portfolio Strategies, LLC | 87,210 | -1,635 (-1.84%) | 0.14% | $1 M | Nov 16, 2026 |
| 44 | Susquehanna Fundamental Investments, LLC | 83,918 | +38,558 (+85.00%) | 0.13% | $1 M | Nov 16, 2026 |
| 45 | Franklin Templeton Inc | 77,996 | New | 0.12% | $1 M | Nov 12, 2026 |
| 46 | Marshall Wace, LLP | 73,276 | New | 0.12% | $0 M | Nov 13, 2026 |
| 47 | Invesco Ltd. | 73,001 | +17,194 (+30.81%) | 0.12% | $0 M | Nov 12, 2026 |
| 48 | Man Group plc | 71,918 | +3,278 (+4.78%) | 0.11% | $0 M | Nov 16, 2026 |
| 49 | Aquatic Capital Management LLC | 71,814 | New | 0.11% | $0 M | Nov 16, 2026 |
| 50 | American Century Companies Inc | 70,062 | +711 (+1.03%) | 0.11% | $0 M | Nov 12, 2026 |
| 51 | Rhumbline Advisers | 54,137 | +3,949 (+7.87%) | 0.09% | $0 M | Nov 10, 2026 |
| 52 | XTX Topco Ltd | 45,060 | +23,162 (+105.77%) | 0.07% | $0 M | Nov 16, 2026 |
| 53 | Bank Of America Corp /de/ | 44,984 | -220,421 (-83.05%) | 0.07% | $0 M | Nov 16, 2026 |
| 54 | Canada Pension Plan Investment Board | 44,700 | +4,700 (+11.75%) | 0.07% | $0 M | Nov 16, 2026 |
| 55 | Banque Cantonale Vaudoise | 40,000 | +6,556 (+19.60%) | 0.06% | $0 M | Nov 12, 2026 |
| 56 | ACT Capital Partners, L.P. | 40,000 | — | 0.06% | $0 M | Nov 6, 2026 |
| 57 | Deutsche Bank AG\ | 39,736 | -5,117 (-11.41%) | 0.06% | $0 M | Nov 6, 2026 |
| 58 | Kera Capital Partners, Inc. | 35,000 | -5,000 (-12.50%) | 0.06% | $0 M | Nov 13, 2026 |
| 59 | PDT Partners, LLC | 31,902 | New | 0.05% | $0 M | Nov 16, 2026 |
| 60 | IFP Advisors, Inc | 29,000 | +16,500 (+132.00%) | 0.05% | $0 M | Oct 16, 2026 |
| 61 | Bridgeway Capital Management, LLC | 27,583 | -122,317 (-81.60%) | 0.04% | $0 M | Nov 16, 2026 |
| 62 | Vanguard Global Advisers, LLC | 26,751 | +11,762 (+78.47%) | 0.04% | $0 M | Nov 13, 2026 |
| 63 | Mitsubishi UFJ Asset Management Co., Ltd. | 25,528 | -213 (-0.83%) | 0.04% | $0 M | Nov 5, 2026 |
| 64 | MetLife Investment Management, LLC | 25,222 | -403 (-1.57%) | 0.04% | $0 M | Nov 16, 2026 |
| 65 | Jpmorgan Chase & Co | 24,887 | +1,903 (+8.28%) | 0.04% | $0 M | Nov 12, 2026 |
| 66 | Y-Intercept (Hong Kong) Ltd | 24,811 | -217,576 (-89.76%) | 0.04% | $0 M | Oct 16, 2026 |
| 67 | Los Angeles Capital Management LLC | 22,531 | +13,948 (+162.51%) | 0.04% | $0 M | Nov 12, 2026 |
| 68 | Alliancebernstein L.P. | 22,100 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 69 | Federated Hermes, Inc. | 22,000 | -8,705 (-28.35%) | 0.03% | $0 M | Nov 12, 2026 |
| 70 | Two Sigma Investments, LP | 21,575 | -29,744 (-57.96%) | 0.03% | $0 M | Nov 16, 2026 |
| 71 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 20,262 | +1,022 (+5.31%) | 0.03% | $0 M | Nov 16, 2026 |
| 72 | Brevan Howard Capital Management LP | 20,144 | New | 0.03% | $0 M | Nov 16, 2026 |
| 73 | Phoenix Wealth Advisors | 19,800 | 0 (0.00%) | 0.03% | $0 M | Nov 3, 2026 |
| 74 | DRW Securities, LLC | 19,325 | New | 0.03% | $0 M | Nov 13, 2026 |
| 75 | Empowered Funds, LLC | 18,683 | New | 0.03% | $0 M | Nov 13, 2026 |
| 76 | Creative Planning | 18,020 | New | 0.03% | $0 M | Nov 2, 2026 |
| 77 | Tower Research Capital LLC (TRC) | 17,893 | +15,540 (+660.43%) | 0.03% | $0 M | Nov 16, 2026 |
| 78 | Vanguard Personalized Indexing Management, LLC | 16,827 | -1,160 (-6.45%) | 0.03% | $0 M | Nov 16, 2026 |
| 79 | AQR Capital Management LLC | 16,380 | New | 0.03% | $0 M | Nov 16, 2026 |
| 80 | Corient Private Wealth LP | 16,000 | New | 0.03% | $0 M | Nov 16, 2026 |
| 81 | Savant Capital, LLC | 15,092 | New | 0.02% | $0 M | Nov 6, 2026 |
| 82 | Baldwin Wealth Partners Llc/ma | 13,969 | New | 0.02% | $0 M | Oct 13, 2026 |
| 83 | Engineers Gate Manager LP | 13,742 | New | 0.02% | $0 M | Nov 16, 2026 |
| 84 | &partners | 13,065 | New | 0.02% | $0 M | Nov 16, 2026 |
| 85 | Police & Firemen's Retirement System of New Jersey | 12,376 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 86 | Caxton Corp | 12,347 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 87 | Ethic Inc. | 12,261 | +438 (+3.70%) | 0.02% | $0 M | Nov 3, 2026 |
| 88 | WINTON GROUP Ltd | 11,800 | -5,600 (-32.18%) | 0.02% | $0 M | Nov 12, 2026 |
| 89 | Samalin Investment Counsel, LLC | 11,595 | 0 (0.00%) | 0.02% | $0 M | Oct 23, 2026 |
| 90 | Oppenheimer & Co Inc | 11,500 | New | 0.02% | $0 M | Oct 26, 2026 |
| 91 | China Universal Asset Management Co., Ltd. | 11,284 | +1,608 (+16.62%) | 0.02% | $0 M | Oct 28, 2026 |
| 92 | Simplex Trading, LLC | 11,175 | New | 0.02% | $0 M | Nov 4, 2026 |
| 93 | HSBC Holdings PLC | 11,166 | New | 0.02% | $0 M | Nov 16, 2026 |
| 94 | North Star Investment Management Corp. | 10,000 | New | 0.02% | $0 M | Oct 27, 2026 |
| 95 | Grey Ledge Advisors, LLC | 10,000 | 0 (0.00%) | 0.02% | $0 M | Nov 2, 2026 |
| 96 | Kovack Advisors, Inc. | 10,000 | New | 0.02% | $0 M | Nov 13, 2026 |
| 97 | New York State Common Retirement Fund | 9,000 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 98 | Royal Bank Of Canada | 7,623 | +746 (+10.85%) | 0.01% | $0 M | Nov 16, 2026 |
| 99 | Osaic Holdings, Inc. | 5,295 | +1,355 (+34.39%) | 0.01% | $0 M | Nov 12, 2026 |
| 100 | Zurcher Kantonalbank (Zurich Cantonalbank) | 4,962 | +1,849 (+59.40%) | 0.01% | $0 M | Nov 10, 2026 |
Mutual funds holding Kyverna Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.40 M | $13 M | 2.2% | <0.01% | +4.2% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.07 M | $10 M | 1.7% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 856,798 | $8 M | 1.4% | 0.06% | −25% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 448,147 | $4 M | 0.71% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 458,351 | $3 M | 0.72% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 352,088 | $3 M | 0.56% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 266,211 | $2 M | 0.42% | 0.03% | +5.9% | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P Kensho New Economies Composite ETFSSGA Funds Management, Inc. | 260,625 | $2 M | 0.41% | 0.08% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 183,789 | $2 M | 0.29% | <0.01% | +56% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 167,964 | $1 M | 0.27% | <0.01% | +51% | May 31, 2026 |
| 🇺🇸 Invesco Dorsey Wright SmallCap Momentum ETFInvesco Capital Management LLC | 166,182 | $1 M | 0.26% | 0.34% | new | May 31, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 177,936 | $1 M | 0.28% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 139,400 | $1 M | 0.22% | 0.08% | +45% | Jun 30, 2026 |
| 🇺🇸 WesMark Small Company FundWESBANCO INVESTMENT DEPARTMENT | 110,300 | $1 M | 0.17% | 0.53% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 87,942 | $1 M | 0.14% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 106,199 | $1 M | 0.17% | 0.08% | new | Jul 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 102,479 | $1 M | 0.16% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 78,440 | $1 M | 0.12% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 65,620 | $1 M | 0.10% | 0.02% | +32% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 64,591 | $1 M | 0.10% | <0.01% | +60% | May 31, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 55,173 | $0 M | 0.09% | 0.07% | −32% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 53,721 | $0 M | 0.08% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 53,664 | $0 M | 0.08% | <0.01% | +69% | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 55,807 | $0 M | 0.09% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 45,656 | $0 M | 0.07% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P. | 46,835 | $0 M | 0.07% | 0.03% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 37,959 | $0 M | 0.06% | <0.01% | +18% | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 34,167 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 30,600 | $0 M | 0.05% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 29,000 | $0 M | 0.05% | 0.17% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 31,215 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 30,651 | $0 M | 0.05% | <0.01% | +70% | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 23,148 | $0 M | 0.04% | <0.01% | +37% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 22,459 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 21,684 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 25,000 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 17,518 | $0 M | 0.03% | 0.06% | −45% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 16,677 | $0 M | 0.03% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 20,135 | $0 M | 0.03% | <0.01% | +9.9% | Jul 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 19,945 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 16,050 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 14,522 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 15,000 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 13,931 | $0 M | 0.02% | 0.05% | new | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 13,600 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 15,873 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS | 12,296 | $0 M | 0.02% | 0.05% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 12,058 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 11,854 | $0 M | 0.02% | 0.06% | −48% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 14,109 | $0 M | 0.02% | <0.01% | +14% | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 9,911 | $0 M | 0.02% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 9,398 | $0 M | 0.01% | 0.04% | +38% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 9,371 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 8,933 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 7,710 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 7,710 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 9,116 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 6,581 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 6,327 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 7,476 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 6,016 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P. | 7,006 | $0 M | 0.01% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 5,694 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 6,614 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 5,077 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 6,020 | $0 M | <0.01% | 0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 5,270 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 4,914 | $0 M | <0.01% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 4,825 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 3,808 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 4,410 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 4,360 | $0 M | <0.01% | <0.01% | +15% | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 4,308 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 3,452 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 3,355 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 3,219 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust | 3,361 | $0 M | <0.01% | 0.02% | no change | May 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 3,729 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 2,914 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP | 3,349 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 2,577 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 2,686 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 1,950 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 1,828 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,470 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 1,648 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,059 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,009 | $0 M | <0.01% | <0.01% | +28% | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 869 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 841 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 517 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 278 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 267 | $0 M | <0.01% | <0.01% | +14% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 93 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Kyverna Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Fred E. CohenDirector | Grant or award | +5,093 | — | — | 21,727 | Form 4 |
| filed | Ian T. ClarkDirector | Grant or award | +5,093 | — | — | 21,727 | Form 4 |
| filed | Beth C. SeidenbergDirector | Grant or award | +5,093 | — | — | 21,727 | Form 4 |
| filed | Christi ShawExecutive Chairperson, Director | Shares withheld for tax | -4,194 | $8.590 | $36 K | 66,741 | Form 4 |
| filed | Mert AktarDirector | Grant or award | +5,093 | — | — | 21,727 | Form 4 |
| filed | Warner Weston BiddleChief Executive Officer, Director | Grant or award | +58,000 | — | — | 58,000 | Form 4 |
| filed | Naji GehchanSee Remarks | Grant or award | +18,000 | — | — | 18,000 | Form 4 |
| filed | Marc GrassoChief Financial Officer | Grant or award | +10,000 | — | — | 10,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Kyverna Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-4.57 reverse split
Trading halts
- 2025-12-15 14:54 UTC, code LUDP, resumed 14:59 UTC
Fails to deliver
- : 7,241 shares at $5.39
- : 4,892 shares at $5.67
- : 9,458 shares at $5.97
- : 4,660 shares at $5.69
- : 3,428 shares at $6.21
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Kyverna Therapeutics, Inc. scorecard#
Passes 4 of the 12 checks that could be worked out: strongest in financial health (3 of 4), weakest in valuation (1 of 4). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.5×Price to book 1.5× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-45.1%Free cash flow is -45.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-3.64 vs -3.33Diluted EPS -3.64 in fiscal 2025 against -3.33 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$161 MNet income -$161 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-64.7%-64.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health3 of 4
- ✓Short-term assets cover short-term liabilities7.8×Current ratio 7.75 at the end of fiscal 2025.
- ✓Debt below equity0.1×Debt to equity 0.11 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $99 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year15.5%Diluted shares up 15.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Kyverna Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 |
|---|---|---|---|---|
| Income statement | ||||
| Research and development | 134+18.9%— | 112+125%— | 50—— | |
| General and administrative | 36+19.8%— | 30+141%— | 12—— | |
| Operating expenses | 170+19.1%— | 143+129%— | 62—— | |
| Operating income | −170—— | −143—— | −62—— | |
| Interest and finance income | 9.1−40.8%— | 15+573%— | 2.3—— | |
| Interest expense and finance costs | 0.5+244%— | 0.1−24.1%— | 0.2—— | |
| Other non-operating income (expense) | 8.5−43.7%— | 15+642%— | 2.0—— | |
| Income tax | 0—— | 0—— | 0—— | |
| Net income attributable to shareholders | −161—— | −127—— | −60—— | |
| Earnings per share, basic | -3.64—— | -3.33—— | -89.61—— | |
| Earnings per share, diluted | -3.64—— | -3.33—— | -89.61—— | |
| Shares, weighted average (basic) | 44+15.5%— | 38+5591%— | 0.7—— | |
| Shares, weighted average (diluted) | 44+15.5%— | 38+5591%— | 0.7—— | |
| Balance sheet | ||||
| Cash and cash equivalents | 124+28.4%42.2% | 97+179%31.7% | 35—46.1% | |
| Short-term investments | 155−18.1%52.8% | 189+727%62.2% | 23—30.4% | |
| Other current assets | 3.7−19.9%1.3% | 4.6+48.1%1.5% | 3.1—4.2% | |
| Current assets | 283−2.6%96.3% | 291+379%95.4% | 61—80.7% | |
| Property, plant and equipment | 1.5−53.8%0.5% | 3.3+43.9%1.1% | 2.3—3.1% | |
| Right-of-use (leased) assets | 3.6−44.8%1.2% | 6.5−0.4%2.1% | 6.5—8.6% | |
| Total assets | 294−3.6%100% | 305+305%100% | 75—100% | |
| Accounts payable | 5.3+14.7%1.8% | 4.6+6.1%1.5% | 4.4—5.8% | |
| Current liabilities | 36+8.1%12.4% | 34+70.0%11.1% | 20—26.4% | |
| Long-term debt | 25—8.4% | — | — | |
| Lease liabilities (non-current) | 0.3−92.3%0.1% | 4.2−20.6%1.4% | 5.2—7.0% | |
| Total liabilities | 62+61.7%20.9% | 38+46.3%12.5% | 26—34.6% | |
| Retained earnings | −425—−145% | −264—−86.5% | −136—−181% | |
| Shareholders' equity | 232−12.9%79.1% | 267—87.5% | −13r−131—−17.5% | |
| Total liabilities and equity | 294−3.6%100% | 305+305%100% | 75—100% | |
| Shares outstanding | 60+39.7%— | 43+3357%— | 1.3—— | |
| Cash-flow statement | ||||
| Depreciation and amortization | 1.8−15.7%— | 2.1+25.0%— | 1.7—— | |
| Share-based compensation | 10+20.6%— | 8.4+276%— | 2.2—— | |
| Cash from operating activities | −154—— | −114—— | −52—— | |
| Capital expenditure | −0.0—— | −2.2—— | −0.6—— | |
| Cash from investing activities | 40—— | −161—— | −8.8—— | |
| Shares issued | 17—— | 0—— | — | |
| Cash from financing activities | 141−58.1%— | 337+480%— | 58—— | |
| Change in cash | 27−55.7%— | 62—— | −3.1—— | |
| Report | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||
| Research and development | 112−18.4%— | 27−11.3%— | 25−30.8%— | 30−19.7%— | 30*−10.4%— | 30+4.3%— | 36+31.1%— | 37+66.5%— | 33*—— | 29—— | 27—— | 22—— | |
| General and administrative | 51+48.9%— | 16+92.0%— | 15+71.8%— | 11+13.2%— | 9.3*+22.6%— | 8.3−13.6%— | 8.6+40.6%— | 10.0+44.9%— | 7.6*—— | 9.6—— | 6.1—— | 6.9—— | |
| Operating expenses | 163−4.9%— | 43+10.8%— | 40−10.9%— | 41−12.7%— | 39*−4.3%— | 39−0.1%— | 44+32.8%— | 47+61.5%— | 41*—— | 39—— | 33—— | 29—— | |
| Operating income | −163—— | −43—— | −40—— | −41—— | −39*—— | −39—— | −44—— | −47—— | −41*—— | −39—— | −33—— | −29—— | |
| Interest and finance income | 7.8−27.2%— | 1.7−16.0%— | 1.9−18.4%— | 2.3−17.6%— | 1.9*−46.7%— | 2.0−54.1%— | 2.4−49.6%— | 2.8+3.3%— | 3.6*—— | 4.4—— | 4.7—— | 2.7—— | |
| Interest expense and finance costs | 2.5+3342%— | 0.7+10300%— | 0.7+4714%— | 0.7+2568%— | 0.4*+1544%— | 0.0−78.1%— | 0.0−64.1%— | 0.0−43.2%— | 0.0*—— | 0.0—— | 0.0—— | 0.0—— | |
| Other non-operating income (expense) | 5.3−49.9%— | 1.0−50.6%— | 1.2−46.9%— | 1.6−40.9%— | 1.5*−58.4%— | 1.9−54.7%— | 2.3−49.7%— | 2.8+4.1%— | 3.6*—— | 4.3—— | 4.6—— | 2.7—— | |
| Net income attributable to shareholders | −158—— | −42—— | −38—— | −40—— | −38*—— | −37—— | −42—— | −45—— | −37*—— | −34—— | −29—— | −27—— | |
| Earnings per share, basic | — | -0.68—— | -0.63—— | -0.66—— | — | -0.85—— | -0.97—— | -1.03—— | — | -0.80—— | -0.67—— | -1.12—— | |
| Earnings per share, diluted | — | -0.68—— | -0.63—— | -0.66—— | — | -0.85—— | -0.97—— | -1.03—— | — | -0.80—— | -0.67—— | -1.12—— | |
| Shares, weighted average (basic) | 62+42.7%— | 62+42.7%— | 61+40.9%— | 60+39.8%— | — | 43+0.6%— | 43+0.2%— | 43+81.9%— | — | 43—— | 43—— | 24—— | |
| Shares, weighted average (diluted) | 62+42.7%— | 62+42.7%— | 61+40.9%— | 60+39.8%— | — | 43+0.6%— | 43+0.2%— | 43+81.9%— | — | 43—— | 43—— | 24—— | |
| Balance sheet | |||||||||||||
| Cash and cash equivalents | 32—16.8% | 32−6.9%16.8% | 32−40.5%14.5% | 32−43.4%12.5% | 124+28.4%42.2% | 34−67.4%18.3% | 53−59.4%23.6% | 57−74.6%21.8% | 97—31.7% | 105—30.9% | 132—36.2% | 224—57.5% | |
| Short-term investments | 139—73.2% | 139+1.3%73.2% | 168+5.9%76.3% | 204+9.9%79.5% | 155−18.1%52.8% | 137−36.9%73.2% | 158−26.3%69.9% | 186+27.7%71.3% | 189—62.2% | 217—64.0% | 215—59.1% | 146—37.3% | |
| Other current assets | 5.7—3.0% | 5.7+50.1%3.0% | 7.1+168%3.2% | 5.3+5.6%2.1% | 3.7−19.9%1.3% | 3.80.0%2.0% | 2.7+2.5%1.2% | 5.0−12.2%1.9% | 4.6—1.5% | 3.8—1.1% | 2.6—0.7% | 5.7—1.5% | |
| Current assets | 176—93.0% | 176+0.8%93.0% | 207−3.6%94.0% | 242−2.4%94.0% | 283−2.6%96.3% | 175−46.2%93.5% | 214−38.6%94.6% | 248−34.0%95.0% | 291—95.4% | 325—95.9% | 349—96.1% | 375—96.3% | |
| Property, plant and equipment | 1.4—0.7% | 1.4−24.1%0.7% | 1.3−38.7%0.6% | 1.3−44.9%0.5% | 1.5−53.8%0.5% | 1.8−43.1%1.0% | 2.2−35.8%1.0% | 2.4−10.2%0.9% | 3.3—1.1% | 3.2—0.9% | 3.4—0.9% | 2.7—0.7% | |
| Right-of-use (leased) assets | 7.5—4.0% | 7.5+73.5%4.0% | 7.8+55.4%3.6% | 8.2+42.1%3.2% | 3.6−44.8%1.2% | 4.3−39.6%2.3% | 5.0−35.5%2.2% | 5.8−32.1%2.2% | 6.5—2.1% | 7.2—2.1% | 7.8—2.2% | 8.5—2.2% | |
| Total assets | 189—100% | 189+1.2%100% | 220−3.0%100% | 257−1.4%100% | 294−3.6%100% | 187−44.8%100% | 227−37.6%100% | 261−33.2%100% | 305—100% | 339—100% | 363—100% | 390—100% | |
| Accounts payable | 3.4—1.8% | 3.4+12.8%1.8% | 2.9−70.4%1.3% | 12+37.0%4.5% | 5.3+14.7%1.8% | 3.0−69.6%1.6% | 9.9+104%4.4% | 8.5+13.7%3.3% | 4.6—1.5% | 9.9—2.9% | 4.9—1.3% | 7.5—1.9% | |
| Current liabilities | 25—13.3% | 25−25.8%13.3% | 23−42.7%10.4% | 30−10.9%11.5% | 36+8.1%12.4% | 34+9.3%18.1% | 40+69.5%17.6% | 33+52.3%12.8% | 34—11.1% | 31—9.1% | 23—6.5% | 22—5.6% | |
| Long-term debt | 25—13.2% | 25—13.2% | 25—11.3% | — | 25—8.4% | — | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 6.2—3.3% | 6.2+365%3.3% | 6.6+184%3.0% | 7.0+112%2.7% | 0.3−92.3%0.1% | 1.3−73.2%0.7% | 2.3−59.5%1.0% | 3.3−49.2%1.3% | 4.2—1.4% | 5.0—1.5% | 5.7—1.6% | 6.5—1.7% | |
| Total liabilities | 56—29.7% | 56+59.8%29.7% | 54+28.8%24.7% | 61+67.7%23.9% | 62+61.7%20.9% | 35−3.5%18.8% | 42+42.3%18.6% | 37+26.4%14.1% | 38—12.5% | 36—10.8% | 30—8.2% | 29—7.4% | |
| Retained earnings | −545—−288% | −545—−288% | −503—−229% | −465—−181% | −425—−145% | −387—−207% | −350—−155% | −308—−118% | −264—−86.5% | −226—−66.6% | −192—−52.7% | −163—−41.7% | |
| Shareholders' equity | 133—70.3% | 133−12.4%70.3% | 166−10.2%75.3% | 196−12.7%76.1% | 232−12.9%79.1% | 152−49.8%81.2% | 184−44.7%81.4% | 224−37.9%85.9% | 267—87.5% | 303—89.2% | 334—91.8% | 361—92.6% | |
| Total liabilities and equity | 189—100% | 189+1.2%100% | 220−3.0%100% | 257−1.4%100% | 294−3.6%100% | 187−44.8%100% | 227−37.6%100% | 261−33.2%100% | 305—100% | 339—100% | 363—100% | 390—100% | |
| Shares outstanding | 63—— | 63+42.8%— | 62+42.4%— | 61+40.1%— | 60+39.7%— | 44+1.5%— | 43+0.2%— | 43+0.2%— | 43—— | 43—— | 43—— | 43—— | |
| Cash-flow statement | |||||||||||||
| Depreciation and amortization | 1.1−32.8%— | 0.1−66.7%— | 0.30.0%— | 0.4−29.9%— | 0.4*−34.6%— | 0.30.0%— | 0.30.0%— | 0.5+3.9%— | 0.6*—— | 0.3—— | 0.3—— | 0.5—— | |
| Share-based compensation | 13+48.4%— | 3.6+34.1%— | 3.5+39.3%— | 3.2+46.7%— | 2.7*+95.5%— | 2.7−20.9%— | 2.5+96.1%— | 2.2−5.1%— | 1.4*—— | 3.4—— | 1.3—— | 2.3—— | |
| Cash from operating activities | −151—— | −35*—— | −40*—— | −42—— | −34*—— | −43*—— | −32*—— | −45—— | −37*—— | −27*—— | −24*—— | −26—— | |
| Capital expenditure | — | −0.2*—— | — | — | — | −0.0*—— | −0.0*—— | 0—— | −0.5*—— | −0.1*—— | −1.0*—— | −0.5—— | |
| Cash from investing activities | −2.8−103%— | 29*+26.4%— | 36*+23.9%— | −50−1000%— | −17*−159%— | 23*+3237%— | 29*—— | 5.6—— | 29*—— | 0.7*—— | −68*—— | −123—— | |
| Shares issued | — | 6.5*—— | — | — | — | — | — | — | — | — | — | — | |
| Cash from financing activities | 151+71941%— | 6.9*+361%— | 3.8*—— | −0.1—— | 141*—— | 1.5*—— | −0.6*—— | −0.4−100%— | −0.2*—— | −0.2*—— | −0.6*—— | 338—— | |
| Change in cash | −2.3—— | 0.0*—— | −0.4*—— | −92—— | 90*—— | −19*—— | −3.4*—— | −40−121%— | −8.1*—— | −27*—— | −93*—— | 190—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Kyverna Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 6 · Material agreement 5 · New debt 1 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersResults announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2021 | $152 M | No. 1 | $50 to $250 million | 24 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Kyverna Therapeutics, Inc.#
$50 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.
- Health Issues1 report
Lobbying firms hired in 2025
AKIN GUMP STRAUSS HAUER & FELD $50 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $320 K | — | 6 |
| 2025 | $50 K | — | 1 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Kyverna Therapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Kyverna Therapeutics, Inc.#
2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $196 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Director, Medical Engagement OperationsNatural Sciences Managers | 1 | $206 K |
| Associate Director, Program ManagementNatural Sciences Managers | 1 | $185 K |
Where: Emeryville, CA 2
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 2 | 2 | $196 K | 2 |
| FY2025 | 1 | 1 | $200 K | 1 |
| FY2023 | 1 | 1 | $165 K | 1 |
| FY2021 | 1 | 1 | $135 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Kyverna Therapeutics, Inc.
Discuss Kyverna Therapeutics, Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 12 November 2026automatic update · Nov 12, 2026
Kyverna Therapeutics, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $42 million.
- Mutual funds: 93 funds hold $65 millionautomatic update · Jul 31, 2026
93 mutual funds in 1 country hold shares of Kyverna Therapeutics, Inc. worth $65 million, about 12.0% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 78 funds added shares and 5 sold; on balance they bought $29 million. Share splits are not counted as trading.
How Kyverna Therapeutics, Inc. compares in Biotechnology
- Market cap$341 M · higher than 53% of 726
- Price / book1.5× · lower than 68% of 534
- FCF yield-45.1% · higher than 26% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Kyverna Therapeutics, Inc.🇺🇸 | $341 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 1, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Kyverna Therapeutics, Inc.? Verify and update this profile — free
Show Kyverna Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.